New biologic drugs, such as monoclonal antibodies and immunotherapies in clinical development, designed to target metastatic colorectal cancer (CRC) and stimulate the immune system to destroy tumor cells are a significant ...
Aug 29, 2017
0
1
Clinical trial results presented in an oral abstract session 3:00pm Monday, June 5 at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 shows promising results for the addition of vemurafenib (anti-BRAF) ...
Jun 5, 2017
0
2
A combination of two HER2-targeted therapies, trastuzumab (Herceptin) and lapatinib (Tykerb), showed clinical benefit in patients with heavily pretreated HER2-positive metastatic colorectal cancer, according to final results ...
Apr 3, 2017
0
1
About 95 percent of colorectal cancers are considered "microsatellite stable" and very few of these cancers respond to immunotherapy, meaning that the vast majority of metastatic colorectal cancer patients are unable to benefit ...
Apr 3, 2017
0
0
Researchers at Uppsala University have identified gene mutations that are associated with the spread of metastases in colorectal cancer. The findings that have recently been published in the journal Cancer Research could ...
Jan 27, 2017
0
7
New SWOG study results show significantly better outcomes for patients with a treatment-resistant form of metastatic colorectal cancer when the BRAF inhibitor vemurafenib is added to a standard treatment. The findings, for ...
Jan 18, 2017
0
3
Patients with metastatic colorectal cancer may be able to lower the risk of the disease worsening, and improve their chances of survival, if they engage in moderate daily exercise, according to new research by investigators ...
Jan 18, 2017
0
1
The fixed combination of trifluridine/tipiracil (trade name: Lonsurf) has been approved since April 2016 for the treatment of metastatic colorectal cancer. The drugs are an option for adult patients with metastatic colorectal ...
Nov 22, 2016
0
0
Massachusetts General Hospital (MGH) investigators have identified a potential mechanism behind the resistance that inevitably develops to cancer treatment with a combination of chemotherapy and antiangiogenic drugs. In a ...
Oct 12, 2016
0
1
Nintedanib improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to results of the phase III LUME-colon 1 trial presented ...
Oct 11, 2016
0
0
